Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05224141
Title Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung small cell carcinoma

Therapies

Carboplatin + Etoposide + MK-7684A

Cisplatin + Etoposide + MK-7684A

Atezolizumab + Cisplatin + Etoposide

Atezolizumab + Carboplatin + Etoposide

Age Groups: senior | adult
Covered Countries USA | FRA | ESP | DEU | AUT


No variant requirements are available.